期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.783335
关键词
hepatocellular carcinoma; liver resection; sorafenib; PD-L1; PD-1
类别
资金
- National Natural Science Foundation of China [81770653]
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZY2017308, 2020HXFH010]
The study aimed to investigate the predictive value of PD-1 and PD-L1 in HCC patients receiving sorafenib treatment. The results showed that PD-L1 overexpression was an independent predictor of recurrence in high-risk patients who received adjuvant sorafenib treatment after curative resection.
ObjectiveThe predicting values of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) were unclear in Hepatocellular carcinoma (HCC) patients who receive sorafenib treatment after curative hepatic resection. MethodsWe retrospectively enrolled HCC patients who received adjuvant sorafenib treatment after curative resection (N = 154), and patients had resection alone (N = 312). Immunohistochemistry was used to assess expression of PD-1 on tumor infiltration immune cells and PD-L1 on HCC cells. Cox proportional hazard models were used to explore association between clinicopathological factors and risk of tumor recurrence. ResultsNo significant difference was detected in RFS (p = 0.542), or OS (p = 0.542) between the resection and sorafenib group and resection alone group. In the 154 patients who received adjuvant sorafenib, expression of PD-1 or PD-L1 was not significantly associated with long-term outcomes. However, in the 122 patients at high risk of postoperative recurrence who had adjuvant sorafenib treatment, characterized by maxim tumor size >= 5 cm, or the presence of macro- or micro-vascular invasion, patients with PD-L1 overexpression (>= 3.0) had significantly worse RFS (p = 0.021), and overexpression of PD-L1 (HR: 1.88, 95%CI: 1.18-2.99, p = 0.008) was identified as an independent risk factor associated with unfavorable RFS. ConclusionOverexpression of PD-L1 serves as an independent predictor of recurrence in HCC patients at high risk of relapse who received adjuvant sorafenib treatment after curative resection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据